JP2017519775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519775A5 JP2017519775A5 JP2016574402A JP2016574402A JP2017519775A5 JP 2017519775 A5 JP2017519775 A5 JP 2017519775A5 JP 2016574402 A JP2016574402 A JP 2016574402A JP 2016574402 A JP2016574402 A JP 2016574402A JP 2017519775 A5 JP2017519775 A5 JP 2017519775A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- aminosterol
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 230000002503 metabolic effect Effects 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical class C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 3
- 230000008901 benefit Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 210000003518 stress fiber Anatomy 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 1
- 241000251778 Squalus acanthias Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 229950001248 squalamine Drugs 0.000 claims 1
- 150000003431 steroids Chemical group 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- WUJVPODXELZABP-FWJXURDUSA-N trodusquemine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCNCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 WUJVPODXELZABP-FWJXURDUSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US62/015,657 | 2014-06-23 | ||
| US14/329,627 | 2014-07-11 | ||
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| PCT/US2015/036935 WO2015200195A1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020007206A Division JP7010979B2 (ja) | 2014-06-23 | 2020-01-21 | 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519775A JP2017519775A (ja) | 2017-07-20 |
| JP2017519775A5 true JP2017519775A5 (enExample) | 2018-06-07 |
| JP6692300B2 JP6692300B2 (ja) | 2020-05-13 |
Family
ID=54869043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574402A Active JP6692300B2 (ja) | 2014-06-23 | 2015-06-22 | 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 |
| JP2020007206A Active JP7010979B2 (ja) | 2014-06-23 | 2020-01-21 | 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020007206A Active JP7010979B2 (ja) | 2014-06-23 | 2020-01-21 | 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10040817B2 (enExample) |
| EP (1) | EP3157531B1 (enExample) |
| JP (2) | JP6692300B2 (enExample) |
| CN (2) | CN113559108A (enExample) |
| BR (1) | BR112016029917A2 (enExample) |
| CA (1) | CA2951720C (enExample) |
| CY (1) | CY1124554T1 (enExample) |
| DK (1) | DK3157531T3 (enExample) |
| ES (1) | ES2878077T3 (enExample) |
| HR (1) | HRP20211005T1 (enExample) |
| HU (1) | HUE054828T2 (enExample) |
| LT (1) | LT3157531T (enExample) |
| MX (2) | MX382442B (enExample) |
| PL (1) | PL3157531T3 (enExample) |
| PT (1) | PT3157531T (enExample) |
| RS (1) | RS62064B1 (enExample) |
| SI (1) | SI3157531T1 (enExample) |
| SM (1) | SMT202100373T1 (enExample) |
| WO (1) | WO2015200195A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| US20180344748A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating chronic inflammatory diseases |
| US11083735B2 (en) * | 2017-09-08 | 2021-08-10 | Enterin, Inc. | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions |
| MA50536A (fr) | 2017-10-30 | 2020-09-09 | Enterin Inc | Nouvelles formes solides de squalamine et procédés pour les produire |
| CN112312917A (zh) * | 2018-03-27 | 2021-02-02 | 因特尔公司 | 用于治疗幻觉及其相关病症的方法和组合物 |
| US20190381071A1 (en) * | 2018-06-13 | 2019-12-19 | Enterin, Inc. | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| EP3829587A4 (en) * | 2018-08-03 | 2022-07-20 | Enterin, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| EP3829537A4 (en) * | 2018-08-03 | 2022-09-21 | Enterin, Inc. | LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF |
| US20230125585A1 (en) * | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| ATE169930T1 (de) | 1993-03-10 | 1998-09-15 | Magainin Pharma | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| WO1996008270A2 (en) | 1994-09-13 | 1996-03-21 | Magainin Pharmaceuticals Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| PT832094E (pt) * | 1995-06-07 | 2004-06-30 | Genaera Corp | Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| DK0910382T3 (da) | 1996-04-26 | 2003-10-06 | Genaera Corp | Squalamin i kombination med andre anticancermidler til behandling af tumorer |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| CA2255856C (en) | 1996-05-17 | 2008-05-13 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
| AU5194998A (en) | 1996-11-01 | 1998-05-29 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and uses therefor |
| EP1105407B1 (en) | 1998-08-12 | 2007-10-10 | Genaera Corporation | Aminosterol compounds and uses thereof |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| WO2002044324A2 (en) * | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| KR20150080013A (ko) * | 2002-01-28 | 2015-07-08 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료용 조성물 |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| CA2606077C (en) | 2005-04-25 | 2013-07-09 | Genaera Corporation | Polymorphic and amorphous salt forms of squalamine dilactate |
| WO2009032321A2 (en) | 2007-09-06 | 2009-03-12 | Genaera Corporation | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| US8623416B2 (en) | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
| JP6165843B2 (ja) | 2012-04-20 | 2017-07-19 | オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| EP2934543B1 (en) | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 MX MX2016017368A patent/MX382442B/es unknown
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 SM SM20210373T patent/SMT202100373T1/it unknown
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en not_active Ceased
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519775A5 (enExample) | ||
| AU2022283769B2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2020059760A (ja) | 神経刺激性ステロイド、組成物およびその使用 | |
| ES2707596T3 (es) | Uso de un agente modificador de hormonas suprarrenales | |
| TW200306801A (en) | Farnesoid X-activated receptor agonists | |
| TW200829244A (en) | Therapeutic combinations 482 | |
| TW201132365A (en) | Lipids, lipid compositions, and methods of using them | |
| US20130059876A1 (en) | Liquid nasal spray containing low-dose naltrexone | |
| CN103739647B (zh) | 用于治疗疾病的NF‑κB的非激素甾体调节剂 | |
| US20150368290A1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| JP2009533457A (ja) | Ｃ−ニトロソから誘導されるニトロキシル供与体 | |
| JP2005508368A (ja) | 高コレステロール濃度に関連した疾患の治療方法 | |
| JP2011503075A (ja) | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド | |
| CN101378752A (zh) | 4-酰氨基吡啶衍生物介导的神经发生 | |
| AU2014248928B2 (en) | Onapristone polymorphic forms and methods of use | |
| CN106163528A (zh) | 用于治疗肝脑病的甾族化合物 | |
| WO2006007312A2 (en) | Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation | |
| HRP20150849T1 (hr) | Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba | |
| EP3512558A1 (en) | Combination of fxr agonists | |
| JP2016530289A (ja) | 重水素化合物 | |
| WO2018057624A4 (en) | Methods and compositions for stimulation and enhancement of regeneration of tissues | |
| JP2016050181A (ja) | 血管炎治療剤 | |
| CN104311622B (zh) | 一种积雪草酸酰胺类衍生物 | |
| EP4153161A1 (en) | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia | |
| CN108218946B (zh) | 一种去氧胆酸类化合物、其制备方法及应用 |